ATRA attenuate proteinuria via downregulation of TRPC6 in glomerulosclerosis rats induced by adriamycin

Area of Science:

• Nephrology
• Molecular Biology
• Pharmacology

Background:

• Glomerulosclerosis is a major cause of kidney disease characterized by proteinuria.
• The molecular mechanisms underlying proteinuria in glomerulosclerosis require further elucidation.
• Identifying therapeutic targets is crucial for managing glomerulosclerosis.

Purpose of the Study:

• To investigate the molecular mechanism of proteinuria in a rat model of glomerulosclerosis.
• To evaluate the protective effects of all-trans retinoic acid (ATRA) on glomerulosclerosis and proteinuria.
• To explore the role of TRPC6 in the pathogenesis and treatment of glomerulosclerosis.

Main Methods:

• Established a rat model of glomerulosclerosis.
• Administered ATRA and assessed serum creatinine, BUN, and 24-h proteinuria.
• Examined pathological and ultrastructural changes using light and transmission electron microscopy.
• Quantified protein expression of TGF-β1, Col-IV, and TRPC6 via immunohistochemistry, RT-PCR, and Western blot.

Main Results:

• Glomerulosclerosis rats exhibited significantly elevated TRPC6 expression compared to controls.
• ATRA treatment down-regulated glomerular TRPC6 expression.
• ATRA administration attenuated glomerulosclerosis and proteinuria, improving Scr and BUN levels.

Conclusions:

• ATRA ameliorates glomerulosclerosis and proteinuria in rats.
• The protective effects of ATRA may be associated with the suppression of TRPC6 expression.
• Targeting TRPC6 presents a potential therapeutic avenue for glomerulosclerosis.